drugset / Trial / NCT00907478

Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)

NCT00907478

Phase 4 Completed 169 enrolled Amgen
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate changes in bone marrow morphology (structure) after long-term exposure to romiplostim.

Timeline

Start
2009-08-11
Primary completion
2014-01-09
Completion
2014-01-14

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Romiplostim Peptide 10 ug/kg Subcutaneous